NExT: NCI Experimental Therapeutics Program
NCI Experimental Therapeutics Program
Purdue University has joined The Chemical Biology Consortium (CBC) in the NCI Experimental Therapeutics (NExT) Program, a national network of scientists with the mission to accelerate cancer drug discovery and development, centered at the Frederick National Laboratory for Cancer Research. Purdue is the only university in Indiana to become part of the network.
The consortium is part of the NCI Experimental Therapeutics (NExT) Program and includes members with expertise in high-throughput screening, structural biology, medicinal chemistry, compound profiling, cancer cell biology, and animal models for oncology. The mission of the NExT Program is to advance clinical practice and bring improved therapies to patients with cancer by supporting the most promising new drug discovery and development projects.
The NExT program will select potential drug candidates, promising cancer targets and appropriate models for testing therapeutic agents to be pursued by the consortium. Then, members will work with researchers from within their institution and other member institutions to generate proposals of how to pursue the targets or address identified challenges in taking them through the drug discovery pipeline.
About NExT at Purdue University
The Purdue NExT Chemical Biology Consortium (CBC) will focus its efforts on accelerating the development and selection of new therapeutic agents for cancer treatment. This will be achieved by devoting Purdue’s unique intellectual and material resources to quickly advance candidates through the drug development pipeline by a process involving bioinformatics analysis, assay development, hit-to-lead development, protein structure determination, lead optimization, compound profiling, and candidate selection and in vivo target validation.
Purdue University contributes exceptional and robust capacity to each element of this pipeline, as exemplified by the current pipeline of two approved drugs and 33 agents that are currently under clinical development. Twenty of these compounds are directed toward oncologic indications (eight pre-clinical; five Phase 1; two Phase 2a; two Phase 2b; and three Phase 3), suggesting that the Purdue NExT CBC team has the collective experience and proven track record of discovery, lead optimization, candidate selection, and formulation experience needed to move agents toward drug approval.
NExT Proposal Schedule
NExT Proposal Schedule. How to Apply.
|Cycle Open for Submission||Submission Deadline|
|September 15, 2017||October 15, 2017|
|January 15, 2018||February 15, 2018|